Clinical trials / NCT07211633
NCT07211633Phase 3Active not recruiting

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Study sponsor: TG Therapeutics, Inc. · TGTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2026-10-31Estimated
Enrollment · participants360Estimated
Source updated2026-09-21Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Primary completion date changed

− Before

31 Dec 2026

+ After

31 Oct 2026

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Area under the curve (AUC) from 0 to Week 24 of Ublituximab

+ After

Measure: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab

Check registry source